# Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer

> **NCT00003264** · PHASE2 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00003264
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2002-02
- **Final completion:** 2002-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003264, "Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00003264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*